GREENVILLE, S.C., Feb. 13 /PRNewswire-FirstCall/ -- Signalife, Inc. Signalife, Inc. announced that it has added Dr. Zachariah P. Zachariah of Ft. Lauderdale, Florida as a medical and business consultant to the Company. Dr. Zachariah has a regional reputation as an active advisor to the state government of Florida and the state university system of Florida as he serves in positions that range from the Chairman of the Finance Committee for the Florida Board of Governors which manages a budget of $7 billion for the entire state university system of Florida, to Director of Cardiology for Holy Cross Hospital of Ft. Lauderdale, Florida, a 500 bed not-for-profit community hospital.
He founded the Fort Lauderdale Heart Institute, while acting as a voluntary professor of medicine to the University Of Miami School Of Medicine, in Miami, Florida. Dr. Zachariah sits on the board of Universal Healthcare since 2006, a regional healthcare insurance provider which employs 300, and generates revenues of approximately $300 million, and has expanded to seven other states in 2007.
Dr. Zachariah not only served as the Chairman of the Governor’s Task Force on the Obesity Epidemic, but also provided a personal financial contribution to Holy Cross Medical Hospital to establish a Wellness Center to encourage employees and local citizens to engage in various activities to improve their health. He is recognized as an innovator in the medical community by offering patients rebates or financial incentives to adopt healthy lifestyles by avoiding harmful habits such as smoking, consuming foods high in fat and/or cholesterol, and control blood pressure.
The prominent cardiologist also acts as a member of the Florida Council 100, which is a group of CEO’s in Florida appointed by the Governor of Florida to identify numerous issues that face Floridians and offer solutions to these problems.
Dr. Zachariah is a Board Certified Cardiologist with his cardiac fellowship completed at the Cleveland Clinic and his residency in Internal Medicine completed at St. Joseph’s Hospital and Medical Center, in Paterson, New Jersey.
“We are fortunate to have Dr. Zachariah act as an advisor to the company as he offers clinical advice from a private cardiologist perspective as well as an extensive background in entrepreneurial business ventures,” states Pamela Bunes, Signalife’s CEO. “I am honored and excited to be working with him on a number of initiatives to create better patient outcomes and improve the quality of their lives. Dr. Zachariah will provide a unique perspective to the company regarding marketability of various product lines in addition to engaging his peers in various applications for the company’s products. We anticipate building a very strong geographical presence in the southeast region to capitalize on this opportunity to work with Dr. Zachariah.”
“I am delighted by the opportunity to work with Signalife management and the R&D team as it to continues its penetration into the marketplace. I intend to evaluate the technology clinically and hope that it will allow us to better identify cardiovascular disease in its earliest stages providing creative solutions to monitor the success or failure of various treatments available to the medical community, “stated Dr. Zachariah. “The commercialization of this technology may allow the medical community to add another valuable medical instrument to its armamentarium in the fight to eradicate cardiovascular disease.”
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Kevin Kading, +1-212-918-4556
Web site: http://www.Signalife.com/
